Multi-Million Dollar Deployment of Mobility Service Assurance Solution Begins in Q4 2017
SAN JOSE, Calif.-Wednesday, October 4th 2017 [ AETOS Wire ]
(BUSINESS WIRE)-- Spirent Communications plc (LSE:SPT), a world leader in lifecycle service assurance solutions, today announced a second tier-1 mobile operator has selected its VisionWorks Mobility Service Assurance (MSA) solution for national deployment. The multi-million dollar deployment will begin in Q4 2017 and extend into 2018. The VisionWorks MSA solution dramatically accelerates identification and resolution of service issues such as poor data throughput for mobile operators. The solution offers an unprecedented ability to proactively test service quality across the end-to-end mobile network and then correlate the results to isolate the root causes of service issues.
The VisionWorks MSA solution enables mobile operators to rapidly launch new network functions and services, reduce operation
...
Read more »
|
Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan -Tuesday, October 3rd 2017 [ AETOS Wire ]
-Estimated Five-Year Overall Survival Rate was 60 Percent and Five-Year Progression-Free Survival Rate was 39 Percent-
-In the 66 Percent of Patients who Achieved Complete Remission, Both Median Overall Survival and Progression-Free Survival Not Yet Reached-
-Long-Term ADCETRIS Data Continue to Support Development Strategy to Establish ADCETRIS as Foundation of Therapy for CD30-Expressing Lymphomas-
(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced final data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed o
...
Read more »
|
BUSAN, South Korea-Tuesday, October 3rd 2017 [ AETOS Wire ]
(BUSINESS WIRE) -- Busan Metropolitan City announced that it would host the 22nd Busan International Film Festival (BIFF) and the Game Show and Trade, All-Round (G-STAR) 2017, an Global Game Exhibition.
The 22nd BIFF will be held from October 12 to 21, with 298 films shown onto 32 screens, while G-STAR 2017, which is emerging as one of the world’s top three gaming events, will take place from November 16 to 19 at BEXCO.
During the Busan International Film Festival (BIFF), 298 films from 75 countries will be projected onto 32 screens at five major cinemas in Busan.
The festival will screen 100 world premieres (76 feature films, 24 short films), 29 international premieres (24 feature films, 5 short films), and 10 New Currents films.
Korea’s “Glass Garden,” directed by Shin Su-won, is set to open the festival. The closing film is “Love Education
...
Read more »
|
Decision Most Beneficial for School Children
Over 1,000 school students from GEMS Wellington International School were educated on the negative impact of sugar consumption and the epidemic of obesity
Dubai, United Arab Emirates -Tuesday, October 3rd 2017 [ AETOS Wire ]
Emirates Hospital’s, a subsidiary of Emirates Healthcare Company, leading paediatrician, Dr Abeer Khayat, renounces the consumption of sugary drinks among children and youth. Sugary soft drinks and energy drinks are taxed in the UAE (effective as of October 1st 2017). The foremost paediatricians from Emirates Hospital have backed this decision as it would benefit school students the most.
Over 1,000 children of the GEMS Wellington International School, Dubai were educated on the benefits of healthy eating habits by Dr Abeer Khayat, paediatric consultant at Emirates Hospital Dubai, during the morning assembly. Through interactive discussion with children, Dr Abeer emphasised
...
Read more »
|
MONTREAL-Thursday, September 28th 2017 [ AETOS Wire ]
(BUSINESS WIRE)-- Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today the publication of its REP 301 study on the activity of REP 2139 and pegylated interferon α-2a (pegIFN) in The Lancet Gastroenterology & Hepatology (www.replicor.com/science/publications).
The REP 301 study assessed the safety and efficacy of REP 2139 combined with pegIFN in patients with chronic HBV / HDV co-infection. This study demonstrated several key breakthroughs in this patient population including: REP 2139-mediated HBsAg reduction to below 1IU/mL dramatically potentiates the activity of pegIFN, that profound functional control of both HBV and HDV can be established in a high proportion of patients, that this function control persists for 1 year after therapy was withdrawn
...
Read more »
| |